Korochkin I M, Kapustina G M, Babenko E V, Zhuravleva N Iu
Sov Med. 1990(3):12-5.
He-Ne laser therapy included in complex of therapeutic methods for patients with unstable angina pectoris is a highly effective treatment modality; it helps essentially reduce the risk of acute myocardial infarction in these patients. Clinical efficacy of laser therapy is confirmed by its favorable action on hemostasis plasma factors, consisting in reduction of fibrinogen level, normalization of antithrombin-III (AT-III), decrease of the level of soluble fibrinomonomer complexes, this indicating a lowering of the blood coagulation potential. Absence of significant changes in plasminogen level may be an indicator of the nonenzymic route of fibrinogen system activation. Sessions of intravenous laser therapy should be administered 2-3 times a week to unstable angina pectoris patients with low AT-III levels, whereas for patients with initially high or normal AT-III levels combined laser therapy is advisable (4-5 daily invasive procedures and 6-8 skin surface ones on the Zakharyin-Head's zones). Measurements of endogenic anticoagulants is an effective means for monitoring laser therapy in this patient population.
对于不稳定型心绞痛患者，氦氖激光疗法作为综合治疗方法的一部分，是一种高效的治疗方式；它能显著降低这些患者发生急性心肌梗死的风险。激光疗法的临床疗效通过其对止血血浆因子的良好作用得到证实，具体表现为纤维蛋白原水平降低、抗凝血酶III（AT-III）正常化、可溶性纤维蛋白单体复合物水平下降，这表明血液凝固潜能降低。纤溶酶原水平无显著变化可能是纤维蛋白原系统非酶促激活途径的一个指标。对于AT-III水平较低的不稳定型心绞痛患者，静脉激光治疗应每周进行2 - 3次，而对于AT-III水平最初较高或正常的患者，建议采用联合激光治疗（每天进行4 - 5次侵入性操作以及在扎卡里因-黑德氏区进行6 - 8次皮肤表面操作）。对内源性抗凝剂进行测量是监测该患者群体激光治疗效果的有效手段。
